Please assess the completion status of the following clinical trial:

Trial Title: A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of Combined Adalimumab Treatment and Active Supervised Training in Patients With Axial Spondyloarthritis (axSpA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants diagnosed with axial spondyloarthritis (axSpA) (either ankylosing spondylitis (AS) or non-radiographic axial spondyloarthritis (nr-axSpA)), fulfilling the Assessment of Spondyloarthritis International Society (ASAS) classification, aged at least 18 years~* Prescription of Humira® (adalimumab) for treating axSpA according to the local product label~* Eligibility for active physiotherapy according to the rheumatologist and physiotherapist~* Participants must have signed written informed consent before starting any study related assessments or procedures.~Exclusion Criteria:~* Participants with total spinal ankylosis based on the investigators' assessments of available radiographs~* Participants who are not eligible for active supervised training or active physiotherapy at the discretion of the rheumatologist and/or the physiotherapist~* Participants with poorly controlled medical condition(s), which in the opinion of the investigator, would put the participant at risk by participation in the protocol~* Any prior treatment with a biologic disease-modifying antirheumatic drugs (DMARD) is prohibited.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Active Supervised Training (AST) (Type: None): Participants with axSpA and treated with adalimumab (HUMIRA®) according to the local product label and local standard of care were to receive active supervised and standardized training (AST).
- Standard of Care (SOC) Physiotherapy (Type: None): Participants with axSpA and treated with adalimumab (HUMIRA®) according to the local product label and local standard of care were to receive standard of care physiotherapy, according to the physiotherapist discretion.

Based on this trial design, predict the completion outcome and termination type (if applicable).